Accessibility Menu
Scilex logo

Scilex(NASDAQ) SCLX

Market Cap$59.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-97%
5 Year-97%
1 Year-29%
1 Month-4%
$6.93
-1.42%
-0.10Today
Scilex last closing stock price
MetricPriceDate
Last closeUSD 6.822026-07-28
Scilex stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-13.01%USD 7.842026-07-21
1 month-4.08%USD 7.112026-06-26
3 month+26.77%USD 5.382026-04-29
Year to date-10.22%USD 7.602025-12-31
1 year-29.42%USD 9.662025-07-28
3 year-94.18%USD 117.242023-07-28
5 year-96.86%USD 217.052021-07-29
Since inception-96.72%USD 214.662021-03-05

Scilex Financials at a Glance

Market Cap

$59.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$33.86M

Net Income (TTM)

-$419.68M

EPS (TTM)

-$40.58

P/E Ratio

-0.17

Dividend

$0.00

Beta (Volatility)

0.49 (Low)

Price

$6.93

Volume

2,357

Open

$6.84

Previous Close

$6.93

Daily Range

$6.80 - $7.07

52-Week Range

$2.62 - $21.34

Estimated Earnings Date

Sep 2, 2026

SCLX News

a scientist uses a pipette to work with medical samples.

Why Shares of Scilex Are Up Monday

James HalleyOct 9, 2023
2valuestocks

Why Shares of Scilex Are Dropping Monday

James HalleySep 18, 2023
Patients in a waiting room

Why Shares of Scilex Slumped This Week

James HalleyApr 28, 2023

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Scilex

Scilex develops medicines for people with pain, focusing on non-opioid options. Its products help those with nerve pain, migraines, and gout. These treatments aim to reduce pain without the risks linked to opioid drugs.

Pain Relief, Unpacked: What Scilex Sells

  • ZTlido (lidocaine patch): Prescription patch for nerve pain after shingles; approximately 91.5% of Q2 2025 revenue; used by adults with post-herpetic neuralgia.
  • ELYXYB (celecoxib oral solution): Liquid medicine for migraine attacks; about 9% of Q2 2025 revenue; targets adults needing fast migraine relief.
  • GLOPERBA (colchicine oral solution): Liquid for preventing gout flares; negative revenue in Q2 2025 due to returns; for adults with gout.
  • SP-102 (SEMDEXA): Gel for back pain injections; not yet approved; targets people with sciatica.
  • SP-103 and SP-104: New pain and fibromyalgia treatments in clinical trials; not yet generating revenue.

Growth Spurts and Strategic Moves

  • Launched ELYXYB in the U.S. in April 2023 and received Health Canada approval for ELYXYB in January 2025.
  • Launched GLOPERBA in the U.S. in June 2024 after licensing from Romeg Therapeutics.
  • Expanded global rights for ZTlido, ELYXYB, and GLOPERBA through licensing deals in 2024-2025.
  • Formed joint venture Scilex Bio in 2025 to develop KDS2010 for obesity and brain diseases.
  • Secured $100 million equity line with Tumim Stone Capital in July 2025 to support operations.

What Makes Scilex Stand Out

Scilex focuses on non-opioid pain relief, aiming to fill gaps in pain management. Its dedicated sales team targets key U.S. prescribers, supporting product reach. The company leverages licensing and partnerships to expand its portfolio and market access.

Five Things You Need to Know

  • Revenue was $10 million in Q2 2025, down 39.5% from Q2 2024.
  • Operating loss was $21 million in Q2 2025, 31.3% worse than Q2 2024.
  • Cash and equivalents were $4.1 million as of June 30, 2025.
  • Management reported substantial doubt about continuing as a going concern in 2025.

Bottom Line

Scilex has built a focused pain management portfolio and expanded through licensing and partnerships. The company faces financial challenges but continues to develop non-opioid therapies for pain.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

34

CEO

Henry H. Ji, PhD

Website

www.scilexholding.com

Headquarters

Palo Alto, CA 94303, US

SCLX Financials

Key Financial Metrics (TTM)

Gross Margin

54.96%

Operating Margin

-817.05%

Net Income Margin

-1239.37%

Return on Equity

190.13%

Return on Capital

N/A

Return on Assets

-142.92%

Earnings Yield

-5.88%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$59.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

8.49M

Volume

2.36K

Avg. Volume

141.09K

Financials (TTM)

Gross Profit

$18.61M

Operating Income

-$276.67M

EBITDA

-$374.35M

Operating Cash Flow

-$3.71M

Capital Expenditure

-$2.88M

Free Cash Flow

-$6.59M

Cash & ST Invst.

$3.36M

Total Debt

$106.36M

Scilex Performance Analysis

Scilex annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 38,034,00021.4%
20232023-12-31USD 46,743,00022.9%
20242024-12-31USD 56,590,00021.1%
20252025-12-31USD 30,253,000-46.5%
Scilex sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3097.8%
Q32025-09-306.7%
Q42025-12-31-54.6%
Q12026-03-3179.7%
Scilex annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -6.09-73.8%
20232023-12-31USD -44.85636.2%
20242024-12-31USD -19.43-56.7%
20252025-12-31USD -36.4887.7%
Scilex sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-228.3%
Q32025-09-30-198.8%
Q42025-12-3186.5%
Q12026-03-31-109.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$8.61M

+72.1%

Gross Profit

$4.17M

+15.1%

Gross Margin

48.37%

N/A

Market Cap

$59.69MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.76M

N/A

Employees

34

N/A

Net Income

-$43.27M

-65.9%

EBITDA

-$39.00M

-72.6%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$3.36M

-42.1%

Total Debt

$106.36M

+156.2%

Accounts Receivable

$29.85M

+181.1%

Inventory

$4.53M

+50.2%

Long Term Debt

$18.29M

+1278.3%

Short Term Debt

$88.07M

+119.2%

Return on Assets

-1.43%

N/A

Return on Invested Capital

1.33%

N/A

Free Cash Flow

-$4.16M

-171.0%

Operating Cash Flow

-$1.11M

-118.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
INOInovio Pharmaceuticals, Inc.
$1.03+6.72%
CTORCitius Oncology, Inc.
$0.54-2.63%
IXHLIncannex Healthcare Limited
$2.96-0.84%
LUCDLucid Diagnostics Inc.
$0.91+1.22%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.22-0.01%
NOKNokia
$8.93-0.03%
JBLUJetBlue Airways
$6.00+0.10%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.15-0.01%

Questions About SCLX

What is the current price of Scilex?

Scilex is trading at $6.93 per share.

What is the 52-week range for Scilex?

Over the past 52 weeks, Scilex has traded between $2.62 and $21.34.

How much debt does Scilex have?

As of the most recent reporting period, Scilex reported total debt of $106.36M.

How much cash does Scilex have on hand?

Scilex reported $3.35M in cash and cash equivalents in its most recent financial results.

What is Scilex’s dividend yield?

Scilex does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services